In Business 32 Years - Since 1980
THE CURRENT TIME at LC Labs is:
|
|
||||||
In Business 32 Years - Since 1980 |
THE CURRENT TIME at LC Labs is: |
|||||
[ABT-578]
|
 |
 |
|
Size |
US $ |
€ |
£ |
¥ |
|
||
|
5 mg |
148 |
112 |
94 |
11300 |
| ||
|
25 mg |
335 |
254 |
212 |
25700 |
| ||
|
100 mg |
685 |
520 |
433 |
52500 |
| ||
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
| Compare Prices and Purity — LC Labs vs. Other Suppliers |
|---|
M.W. 966.21
C52H79N5O12
[221877-54-9]
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO. Disposal: A
Find and View a Certificate of Analysis for this product
View the MSDS for this product
Zotarolimus (also known as ABT-578) is an analogue of rapamycin (sirolimus) that was designed to have a shorter in vivo half-life than rapamycin. Zotarolimus was found to be comparable in potency for inhibiting in vitro proliferation of both rat and human T cells and mechanistically similar to sirolimus in having high-affinity binding to the immunophilin FKBP12. Chen, Y.W., et al. "Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression." J. Cardiovasc. Pharmacol. 49: 228-235 (2007).
In vitro, zotarolimus inhibited FKBP-12 binding (IC50 = 2.8 nM) and potently blocked smooth muscle cell (IC50 = 2.9 nM) and endothelial cell (IC50 = 2.6 nM) proliferation. After 28 days, zotarolimus stents from domestic juvenile swine exhibited less area stenosis (22.4% vs. 35.7%), less neointimal area (1.69 vs. 2.78 mm2), less neointimal thickness (0.25 vs. 0.38 mm), and greater lumen area (6.07 vs. 5.02 mm2) when compared to phosphorylcholine-coated stents. Garcia-Touchard, A., et al. "Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks." Eur. Heart J. 27: 988-993 (2006).
Zotarolimus was also designed for use in stents that have phosphorylcholine as a carrier.
Zotarolimus is the active drug in the drug-eluting stents sold under the trade name Endeavor® and ZoMaxx®. NOTE: The zotarolimus sold by LC Laboratories is NOT Endeavor® or ZoMaxx®, and is NOT for human use.
Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
Not available in some countries; not available to some institutions; not available for some uses.
Please see also our other standard immunosuppressant products:
Our products are for laboratory research only and are sold only to qualified research institutions, not to individuals or patients nor for veterinary use.
